Last reviewed · How we verify

NCT00691717

A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed Phase 2/Phase 3 Last updated 27 November 2012
What this trial tests

Phase 2/Phase 3 trial testing Anecortave Acetate Sterile Suspension, 30 mg/mL in Open-angle Glaucoma in 201 participants. Completed in 1 September 2009.

Timeline
1 June 2008
Primary endpoint
1 September 2009
1 September 2009

Quick facts

Lead sponsorAlcon Research
PhasePhase 2/Phase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment201
Start date1 June 2008
Primary completion1 September 2009
Estimated completion1 September 2009
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Alcon Research — full company profile →

Who can join

18 and older, any sex, with Open-angle Glaucoma or Oular Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study was to evaluate the safety and intraocular-lowering efficacy of anecortave acetate depot when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Open-angle Glaucoma

Currently open trials in the same condition.

Other Alcon Research trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00691717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing